Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled...

Related Keywords

Japan ,Tokyo ,London ,City Of ,United Kingdom ,Amsterdam ,Noord Holland ,Netherlands ,United States ,Canada ,Australia ,America ,Hirokazu Kanegane ,Claire Dobbs ,Ethan Metelenis ,Heather Robertson ,Anurag Relan ,Michael Levitan ,Devices Agency ,Ministry Of Health ,Prnewswire Pharming Groupnv ,European Medicines Agency ,Vp Investor Relations Corporate Communications ,Investor Relations Corporate Communications ,Japan Pharmaceuticals ,Professor Of The Department Child Health ,Drug Administration ,Pharming Group ,Nasdaq ,Lifespring Life Sciences Communication ,Exchange Commission ,Single Arm Phase ,Medical Devices Agency ,Child Health ,Tokyo Medical ,Dental University ,Chief Medical Officer ,United States Food ,Activated Phosphoinositide ,North America ,Middle East ,Looking Statements ,Annual Report ,Allergy Clin ,Rev Allergy ,Corporate Communications ,Investor Relations ,Corporate Communications Manager ,Amy Byrne ,Spring Life Sciences Communication ,Pharming Groupnv ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Banking Amp Financial Services ,Clinical Trials Amp Medical Discoveries ,